Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance
Version 2 2024-06-13, 08:59
Version 1 2015-03-20, 12:31
journal contribution
posted on 2024-06-13, 08:59 authored by F Al-Ejeh, AH Staudacher, DR Smyth, JM Darby, D Denoyer, C Tsopelas, RJ Hicks, MP BrownEarly identification of tumor responses to treatment is crucial for devising more effective and safer cancer treatments. No widely applicable, noninvasive method currently exists for specifically detecting tumor cell death after cytotoxic treatment and thus for predicting treatment outcomes.
History
Journal
JNM : The journal of nuclear medicineVolume
55Pagination
772-779Location
New York, N.Y.Publisher DOI
Open access
- Yes
Link to full text
eISSN
1535-5667Language
engPublication classification
C Journal article, C1.1 Refereed article in a scholarly journalCopyright notice
2014, Society of Nuclear MedicineIssue
5Publisher
Society of Nuclear MedicineUsage metrics
Keywords
APOMABDAB4Laapoptosischemotherapytherapy responseAnimalsAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsApoptosisAutoantigensBinding, CompetitiveCell ProliferationDNA Breaks, Double-StrandedFemaleFlow CytometryHumansJurkat CellsLymphomaMaleMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasm TransplantationProstatic NeoplasmsProtein BindingRadionuclide ImagingRibonucleoproteinsThymocytesThymus NeoplasmsTreatment Outcome111201 Cancer Cell Biology970106 Expanding Knowledge in the Biological SciencesCentre for Chemistry and BiotechnologySchool of Life and Environmental Sciences
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC